Sensus Healthcare Reports Third Quarter 2022 Financial Results Profitability continues with revenues up 64% to $9.0 million, diluted EPS of $0.11 compares with $0.01 a year ago Conference call begins at 4:30 p.m. Eastern

Healthcare Reports Third Quarter 2022 Financial Results

continues with revenues up 64% to $9.0 million, diluted EPS of $0.11 compares with $0.01 a year ago

call begins at 4:30 p.m. Eastern time today

RATON, Fla. (November 3, 2022) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective,

non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results

for the three and nine months ended September 30, 2022.

from the third quarter of 2022 and recent weeks include the following (all comparisons are with the third quarter of 2021, unless otherwise

continue to execute very well on our strategy and once again generated strong growth in revenues, and profits," said

Joe Sardano, chairman and chief executive officer of Sensus Healthcare. "We remain focused on our core dermatology business,

providing products our customers and their patients need. To that end, we launched important upgrades to our premium SRT-100 Vision

system that included new state-of-the-art, solid-state, high-frequency ultrasound, which provides the best view of the epidermis in

the market and utilizes a new ergonomically designed probe employing single-use disposables. The Vision model has become our leading

SRT product, helped by these design upgrades and our fair market leasing program. That said, higher interest rates are impacting

physician ROI, but not demand."

Sardano added, "Our recently acquired TransDermal Infusion System for the needleless and pain-free delivery of aesthetic medicines

is generating significant attention at trade shows and medical conferences. Research by key opinion leaders Dr. Mark Nestor and Dr. Glynis

Ablon continues to support our marketing efforts. At the Fall Clinical Dermatology Conference, Dr. Nestor presented his success with

the TDI system to deliver onabotulinumtoxinA, better known as Botox, in hyperhidrosis patients, and Dr. Ablon presented on the ability

of the TDI system to deliver finasteride for hair growth without pain. During the third quarter we took orders for 10 TDI systems from

Hair Enhancement Centers, delivered one during the quarter, and expect to deliver the remaining nine before the end of the year.

continue to see good uptake on our service agreements, with approximately 40% of customers having committed to these agreements

following the expiration of the one-year warranty. We expect service agreements to be a growing source of recurring revenue,"

Mr. Sardano continued. "Of note, we believe the treatment of non-melanoma skin cancer is not impacted by economic uncertainty,

but a recession could affect aesthetic procedures. The devastation from Hurricane Ian to large parts of Florida may impact fourth

quarter sales as some of our largest customers have not yet reopened their clinics. However, we are continuing to plan for growth

and expect additional hiring in our sales organization."

Quarter Financial Results

for the third quarter of 2022 were $9.0 million, compared with $5.5 million for the third quarter of 2021. The 64% increase was driven

by a higher number of units sold, increased service revenue and the impact of COVID-19 on 2021 results.

of sales for the third quarter of 2022 was $3.1 million, compared with $2.3 million for the prior-year quarter. The increase was due

to higher sales in 2022.

profit for the third quarter of 2022 was $5.9 million, or 65.6% of revenues, compared with $3.2 million, or 57.9% of revenues, for the

third quarter of 2021. The increases were driven by a higher number of units sold in 2022, service revenue on installed units and the

impact of COVID-19 on 2021 results.

and marketing expense for the third quarter of 2022 was $1.8 million, compared with $1.2 million for the third quarter of 2021. The increase

was attributable to higher tradeshow and advertising expense.

and administrative expense for the third quarter of 2022 was $1.2 million, compared with $1.1 million for the third quarter of 2021.

The increase was primarily due to higher professional fees.

and development expense for the third quarter of 2022 was $0.7 million, unchanged from the prior-year quarter.

for income taxes was $0.5 million for the third quarter of 2022, compared with no income tax provision for the prior-year quarter.

income for the third quarter of 2022 was $1.8 million, or $0.11 per diluted share, compared with net income of $0.2 million, or $0.01

per diluted share, for the third quarter of 2021.

EBITDA for the third quarter of 2022 was $2.3 million, compared with $0.5 million for the third quarter of 2021. Adjusted EBITDA, a non-GAAP

financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation expense. Please see

below for a reconciliation between GAAP and non-GAAP financial measures, and the specific reasons these non-GAAP financial measures are

and cash equivalents were $37.6 million as of September 30, 2022, compared with $14.5 million as of December 31, 2021. The company had

no outstanding borrowings under its revolving line of credit as of September 30, 2022 or December 31, 2021.

Month Financial Results

for the first nine months of 2022 were $31.4 million, compared with $14.0 million for the first nine months of 2021. The 124% increase

was driven by a higher number of units sold in 2022, service revenue on installed units and the impact of COVID-19 on 2021 results.

of sales was $10.2 million for the nine months ended September 30, 2022, compared with $5.9 million for the nine months ended September

30, 2021. The increase was due to higher sales in 2022.

profit for the first nine months of 2022 was $21.3 million, or 67.8% of revenue, compared with $8.1 million, or 58.0% of revenue, for

the same period of 2021. The increases were driven by a higher number of units sold in 2022, service revenue on installed units and the

impact of COVID-19 on 2021 results.

and marketing expense was $4.8 million for the nine months ended September 30, 2022, compared with $3.5 million for the nine months ended

September 30, 2021. The increase was primarily attributable to higher tradeshow, advertising and commission expense.

and administrative expense was $3.6 million for the first nine months of 2022, compared with 3.5 million in the prior-year period. The

increase was primarily due to higher professional fees.

and development expense of $2.3 million for the first nine months of 2022 was unchanged from the first nine months of 2021.

Company reported other income of $12.9 million during the first nine months of 2022, which was mostly related to the gain on sale of

a non-core asset. There was no other income in 2021.

income for the first nine months of 2022 was $21.4, or $1.28 per diluted share, compared with a net loss of $(1.2) million, or $(0.07)

per share, for the prior-year period. Net income for the nine months ended September 30, 2022 excluding gain on sale of assets was $8.6

million, or $0.52 per diluted share.

EBITDA for the first nine months of 2022 was $23.8 million, compared with $(0.4) million for the first nine months of 2021.

of Non-GAAP Financial Information

press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally

accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis

of performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed as a substitute

for operating results determined in accordance with GAAP. Management believes the presentation of Adjusted EBITDA, which excludes the

impact of interest, income taxes, depreciation, amortization and stock-compensation expense, provides useful supplemental information

that is essential to a proper understanding of the financial results of Sensus Healthcare. Non-GAAP financial measures are not formally

defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement to

GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts

who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation

of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.

TO NON-GAAP RECONCILIATION

Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management will discuss

financial results for the third quarter of 2022, provide a business update and answer questions. To access the conference call, dial

866-777-2509 (U.S. and Canada Toll Free) or 412-317-5413 (International). The call will be webcast live and can be accessed at this link,

or in the Investors section of the Company's website at www.sensushealthcare.com.

the conclusion of the conference call, a replay will be available until December 3rd and can be accessed by dialing 877-344-7529

(U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International), using replay code 4619519. An archived webcast of

the call will also be available in the Investors section of the Company's website.

Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments

for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation

therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids

with its SRT-100 , SRT-100+ and SRT-100 Vision systems. With its portfolio of innovative

medical device products, including aesthetic lasers and its needleless TransDermal Infusion System , Sensus provides

revolutionary treatment options to enhance the quality of life of patients around the world.

more information, visit www.sensushealthcare.com.

press release includes statements that are, or may be deemed, "forward-looking statements.'' In some cases, these statements can be

identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects,"

"plans," "intends," "may," "could," "might," "will," "should,"

"approximately," "potential" or negative or other variations of those terms or comparable terminology, although

not all forward-looking statements contain these words.

statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry,

and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to